References
- Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616.
- Adams R, Maroof A, Baker T, G LAD, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01894.
- Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8:130.
- Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–7.
- Wilke AC, Gökbuget N. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf. 2017;16:1191–202.
- Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (Removab). J Cancer. 2011;2:309–16.
- Schmitt C, Adamkewicz JI, Xu J, Petry C, Catalani O, Young G, Negrier C, Callaghan MU, Levy GG. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost. 2021;121:351–60.
- Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983;305:537–40.
- Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–47.
- Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2 Pt A):95–106. doi:10.1016/j.molimm.2015.01.003.
- Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212.
- Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 1999;453:164–68.
- Ridgway JBB, Presta LG, Carter PJ. ‘knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9:617–21.
- Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, B NS, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem. 2010;285:19637–46.
- Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868–76.
- Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK. Advances in antibody-drug conjugates: a new era of targeted cancer therapy. Drug Discov Today. 2017;22:1547–56.
- Szijj P, Chudasama V. The renaissance of chemically generated bispecific antibodies. Nat Rev Chem. 2021;5:78–92.
- Weininger D. SMILES, a chemical language and information system. 1. introduction to methodology and encoding rules. J Chem Inf Comput Sci. 1988;28:31–36.
- Zhang T, Li H, Xi H, Stanton RV, Rotstein SH. HELM: a hierarchical notation language for complex biomolecule structure representation. J Chem Inf Model. 2012;52:2796–806.
- Dal Corso A, Pignataro L, Belvisi L, Gennari C. Innovative linker strategies for tumor-targeted drug conjugates. Chem Eur J. 2019;25:14740–57.